Quest Diagnostics

YTD

ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell DGX and other ETFs, options, and stocks.

About DGX

Quest Diagnostics, Inc. engages in the provision of diagnostic testing, information, and services. It operates through the Diagnostic Information Services (DIS) and All Other segments.

CEO

James E. Davis

CEOJames E. Davis

Employees

57,000

Employees57,000

Headquarters

Secaucus, New Jersey

HeadquartersSecaucus, New Jersey

Founded

1967

Founded1967

Employees

57,000

Employees57,000

DGX Key Statistics

Market cap

25.42B

Market cap25.42B

Price-Earnings ratio

24.48

Price-Earnings ratio24.48

Dividend yield

1.44%

Dividend yield1.44%

Average volume

1.12M

Average volume1.12M

High today

$231.96

High today$231.96

Low today

$228.56

Low today$228.56

Open price

$230.22

Open price$230.22

Volume

94.11K

Volume94.11K

52 Week high

$248.84

52 Week high$248.84

52 Week low

$171.18

52 Week low$171.18

Stock Snapshot

With a market cap of 25.42B, Quest Diagnostics(DGX) trades at $230.30. The stock has a price-to-earnings ratio of 24.48 and currently yields dividends of 1.44%.

On 2026-10-09, Quest Diagnostics(DGX) stock moved within a range of $228.56 to $231.96. With shares now at $230.30, the stock is trading +0.8% above its intraday low and -0.7% below the session's peak.

Trading activity shows a volume of 94.11K, compared to an average daily volume of 1.12M.

The stock's 52-week range extends from a low of $171.18 to a high of $248.84.

DGX News

Simply Wall St 7h

Is Quest Diagnostics Undervalued Following New Haystack MRD Study Results?

A new clinical study on Quest Diagnostics (DGX) Haystack MRD test reported high accuracy in detecting residual and recurrent solid tumor cancers, giving investo...

TipRanks 2d

Quest Diagnostics price target raised to $260 from $250 at Barclays

Barclays analyst Luke Sergott raised the firm’s price target on Quest Diagnostics (DGX) to $260 from $250 and keeps an Overweight rating on the shares. The firm...

TipRanks 3d

Quest Diagnostics announces executive transition and leadership continuity

Quest Diagnostics ( (DGX) ) has provided an announcement. On October 6, 2026, Quest Diagnostics announced that long-time executive Catherine T. Doherty will re...

Analyst ratings

50%

of 20 ratings

Buy

45%

Hold

50%

Sell

More DGX News

Simply Wall St 5d

How Investors May Respond To Quest Diagnostics Solid Tumor Test Validation

Quest Diagnostics reported that its Haystack MRD liquid biopsy, evaluated in a new Journal of Molecular Diagnostics study, showed high accuracy detecting residu...

People also own

Based on the portfolios of people who own DGX. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.